Table 1 Characteristics of participants and inclusion/exclusion criteria

Sex

Key Inclusion Criteria

1) Between 18 and 75 years of age

2) Clinically definite Multiple Sclerosis

3) On Glatiramer Acetate for at least 3 months

4) No relapse within 3 months

 Female (%)

13 (72)

16 (100)

 Male (%)

5 (28)

0 (0)

Age in years ± SD (range)

54.4 ± 9.0 (32–72)

54.1 ± 8.7 (39–72)

Weight in kg ± SD (range)

70.0 ± 12.8 (51.3–95.6)

72.5 ± 12.6 (50.0–91.6)

MS type

Key Exclusion Criteria

1) No MS treatment or treated with beta-interferon, Tysabri, Fingolimod, Tecfidera, Aubagio, Lemtrada, corticosteroids, or other immunosuppressive therapy in the previous 3 months

2) Have taken GlcNAc or glucosamine in the previous 3 months

3) Weight less than 110 lb. (50 kg) or greater than 220 lb. (100 kg)

4) Type 1 diabetes, Type 2 diabetes poorly controlled (HbA1c > 6.5%), type 2 diabetes on insulin, vascular disease, coronary artery disease, stroke, or transient ischemic attack, cancer, organ transplant, bleeding disorder, chronic respiratory disease, including asthma, chronic renal failure, chronic liver disease, or seizure disorder

5) Pregnancy, < 6-month postpartum, breast feeding postpartum

 RRMS (%)

9 (50)

9 (56)

 SPMS (%)

7 (39)

5 (31)

 PPMS (%)

2 (11)

2 (13)

EDSS ± SD (range)

3.8 ± 2.1 (0–75)

3.8 ± 2.0 [1–8]

MS Therapy

 Therapy Copaxone (%)

18 (100)

16 (100)

 Other (%)

0 (0)

0 (0)